Patent · US Active

3-(imidazolyl)-pyrazolo[3,4-b] pyridines

US8481545B2 · kind B2 · utility

1Cited by

9References

12Claims

0Family size

Assignee

CHEMOCENTRYX, INC. · US

Inventors

Lianfa Li · Palo Alto, US
Andrew Pennell · San Francisco, US
Penglie Zhang · Foster City, US

Key dates

Filing date	May 9, 2011
Grant date	Jul 9, 2013
Priority date	—
Expiry date	May 9, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.